CL2020003101A1 - Sales de sepiapterina farmacéuticamente aceptables. - Google Patents
Sales de sepiapterina farmacéuticamente aceptables.Info
- Publication number
- CL2020003101A1 CL2020003101A1 CL2020003101A CL2020003101A CL2020003101A1 CL 2020003101 A1 CL2020003101 A1 CL 2020003101A1 CL 2020003101 A CL2020003101 A CL 2020003101A CL 2020003101 A CL2020003101 A CL 2020003101A CL 2020003101 A1 CL2020003101 A1 CL 2020003101A1
- Authority
- CL
- Chile
- Prior art keywords
- sepiapterin
- salts
- relates
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
- VPVOXUSPXFPWBN-VKHMYHEASA-N sepiapterin Chemical class N1C(N)=NC(=O)C2=C1NCC(C(=O)[C@@H](O)C)=N2 VPVOXUSPXFPWBN-VKHMYHEASA-N 0.000 title abstract 5
- VPVOXUSPXFPWBN-UHFFFAOYSA-N L-sepiapterin Natural products N1=C(N)NC(=O)C2=C1NCC(C(=O)C(O)C)=N2 VPVOXUSPXFPWBN-UHFFFAOYSA-N 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 4
- 229940126478 sepiapterin Drugs 0.000 title abstract 4
- 239000013078 crystal Substances 0.000 abstract 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 abstract 1
- 229960004617 sapropterin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/04—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/30—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/06—Glycolic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862678025P | 2018-05-30 | 2018-05-30 | |
| US201862726612P | 2018-09-04 | 2018-09-04 | |
| US201962822336P | 2019-03-22 | 2019-03-22 | |
| GC201937661 | 2019-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020003101A1 true CL2020003101A1 (es) | 2021-05-14 |
Family
ID=68699017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020003101A CL2020003101A1 (es) | 2018-05-30 | 2020-11-27 | Sales de sepiapterina farmacéuticamente aceptables. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210269443A1 (enExample) |
| EP (1) | EP3807279B1 (enExample) |
| JP (2) | JP7778477B2 (enExample) |
| KR (1) | KR20210038848A (enExample) |
| CN (1) | CN112543758A (enExample) |
| AU (2) | AU2019277372B2 (enExample) |
| BR (1) | BR112020024332A2 (enExample) |
| CA (1) | CA3102070A1 (enExample) |
| CL (1) | CL2020003101A1 (enExample) |
| CO (1) | CO2020016582A2 (enExample) |
| IL (1) | IL279101A (enExample) |
| MX (1) | MX2020012978A (enExample) |
| WO (1) | WO2019232120A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| FI3801536T3 (fi) | 2018-05-30 | 2024-08-29 | Ptc Therapeutics Mp Inc | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi |
| EP3801534B1 (en) * | 2018-05-30 | 2026-02-18 | PTC Therapeutics MP, Inc. | Treatment of phenylketonuria with sepiapterin |
| AU2019277372B2 (en) * | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| IL290321B1 (en) | 2019-08-05 | 2026-04-01 | Ptc Therapeutics Inc | Use of spiapterin and its metabolites for radiation exposure treatment |
| IL291565B1 (en) | 2019-09-25 | 2026-04-01 | Ptc Therapeutics Inc | Method for treating phenylalanine irregularity |
| EP4093405A1 (en) | 2020-01-24 | 2022-11-30 | PTC Therapeutics MP, Inc. | Methods for treating parkinson's disease with sepiapterin |
| CN114621198B (zh) | 2020-12-11 | 2025-01-21 | 北京夏禾科技有限公司 | 有机电致发光材料及其器件 |
| IL305037A (en) | 2021-02-09 | 2023-10-01 | Ptc Therapeutics Mp Inc | Methods of treating glioblastomas with spiafatrin |
| WO2022173823A1 (en) | 2021-02-09 | 2022-08-18 | Ptc Therapeutics Mp, Inc. | Methods for treating covid-19 with sepiapterin |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| EP0722731B1 (en) * | 1994-08-05 | 2002-06-05 | Suntory Limited | Remedy for spinocerebellar degeneration |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| LT2545939T (lt) * | 2007-04-11 | 2021-03-10 | Biomarin Pharmaceutical Inc. | Tetrahidrobiopterinas, skirtas gydyti ligas, susijusias supadidėjusiu fenilalanino kiekiu |
| CN102256976A (zh) | 2008-12-23 | 2011-11-23 | 贝林格尔.英格海姆国际有限公司 | 有机化合物的盐形式 |
| EP2562176B1 (en) * | 2010-04-22 | 2018-08-15 | Nihon University | Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same |
| CN104736539B (zh) * | 2012-05-07 | 2017-09-01 | 白鸟制药株式会社 | 墨蝶呤和四氢乳酰蝶呤的制造法 |
| EP3468534A4 (en) * | 2016-06-13 | 2020-02-05 | Meharry Medical College | MODULATION OF THE NITROGEN OXIDE SYNTHASE SIGNAL PATH FOR ORAL HEALTH |
| MA46973A (fr) * | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| JP7811085B2 (ja) * | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| AU2019277372B2 (en) * | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
-
2019
- 2019-05-30 AU AU2019277372A patent/AU2019277372B2/en active Active
- 2019-05-30 BR BR112020024332-9A patent/BR112020024332A2/pt unknown
- 2019-05-30 CA CA3102070A patent/CA3102070A1/en active Pending
- 2019-05-30 CN CN201980050845.2A patent/CN112543758A/zh active Pending
- 2019-05-30 WO PCT/US2019/034505 patent/WO2019232120A1/en not_active Ceased
- 2019-05-30 JP JP2020566701A patent/JP7778477B2/ja active Active
- 2019-05-30 MX MX2020012978A patent/MX2020012978A/es unknown
- 2019-05-30 US US17/059,887 patent/US20210269443A1/en active Pending
- 2019-05-30 KR KR1020207037815A patent/KR20210038848A/ko not_active Ceased
- 2019-05-30 EP EP19811127.0A patent/EP3807279B1/en active Active
-
2020
- 2020-11-27 CL CL2020003101A patent/CL2020003101A1/es unknown
- 2020-11-30 IL IL279101A patent/IL279101A/en unknown
- 2020-12-29 CO CONC2020/0016582A patent/CO2020016582A2/es unknown
-
2024
- 2024-02-29 JP JP2024030700A patent/JP7841008B2/ja active Active
-
2025
- 2025-02-13 AU AU2025201002A patent/AU2025201002A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL279101A (en) | 2021-01-31 |
| US20210269443A1 (en) | 2021-09-02 |
| WO2019232120A1 (en) | 2019-12-05 |
| JP7778477B2 (ja) | 2025-12-02 |
| CA3102070A1 (en) | 2019-12-05 |
| BR112020024332A2 (pt) | 2021-02-23 |
| JP2024063143A (ja) | 2024-05-10 |
| CN112543758A (zh) | 2021-03-23 |
| MX2020012978A (es) | 2021-04-28 |
| EP3807279A4 (en) | 2022-04-06 |
| CO2020016582A2 (es) | 2021-04-08 |
| JP2021527031A (ja) | 2021-10-11 |
| JP7841008B2 (ja) | 2026-04-06 |
| EP3807279B1 (en) | 2025-12-31 |
| EP3807279A1 (en) | 2021-04-21 |
| AU2019277372B2 (en) | 2024-12-19 |
| KR20210038848A (ko) | 2021-04-08 |
| AU2019277372A1 (en) | 2021-01-21 |
| AU2025201002A1 (en) | 2025-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020003101A1 (es) | Sales de sepiapterina farmacéuticamente aceptables. | |
| CY1124789T1 (el) | Πυριμιδιν-2-υλαμινο-1η-πυραζολια ως αναστολεις lrrk2 για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων | |
| CY1124548T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου | |
| MX2024006689A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| CL2018002727A1 (es) | Medicina obtenida mediante la combinación de agonista fxr y arb | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| SA518391624B1 (ar) | Ror- منظمات جاما | |
| MX383856B (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| EA201790528A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
| MX2018003331A (es) | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. | |
| EA201691134A1 (ru) | Новые ингибиторы глутаминазы | |
| DOP2016000156A (es) | Composiciones farmacã¿uticas que comprenden azd9291. | |
| JOP20180036A1 (ar) | أملاح لمثبطات فروبورتين جديدة | |
| CY1123532T1 (el) | Αναστολεις του gingipain λυσινης | |
| BR112017002403A2 (pt) | formas de cristais de inibidores de glutaminase | |
| CL2021001537A1 (es) | Formas cristalinas y formas de sal de un inhibidor de cinasa | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| GT201600250A (es) | Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| EA201990428A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| CY1124115T1 (el) | Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες | |
| JOP20200100A1 (ar) | مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3 | |
| BR112020008258B8 (pt) | Compostos de biarila substituída ou seus sais farmaceuticamente aceitáveis, sua composição e seu uso como inibidores de indoleamina 2,3-dioxigenase (ido) | |
| EA201790315A1 (ru) | Модуляторы x-рецепторов печени | |
| CY1121345T1 (el) | Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης | |
| CO2021017343A2 (es) | Formas de sales cristalinas de un inhibidor de cinasas |